IMA950

BIOLOGICAL2 trials

Sponsors

Immatics Biotechnologies GmbH, Nicholas Butowski

Conditions

Astrocytoma, Grade IIGlioblastomaGliomaGlioma, AstrocyticMalignant GliomaOligoastrocytoma, MixedOligodendroglioma

Phase 1

Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma

TerminatedNCT01403285

Immatics Biotechnologies GmbHGlioblastoma

Start: 2011-08-31End: 2014-04-30Updated: 2014-05-19

A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)

TerminatedNCT02924038

Nicholas ButowskiAstrocytoma, Grade II, Glioma, Glioma, Astrocytic +3

Start: 2017-04-03End: 2022-12-31Updated: 2024-06-14